News
JANX
47.93
+1.76%
0.83
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. The company's main pipeline candidate, CX-904, is being assessed in a phase 1 trial. CTMX has 1.5 years of cash runway to fund operations. Right now, there is a surge of interest in masked immunotherapies.
Seeking Alpha · 22h ago
Weekly Report: what happened at JANX last week (0415-0419)?
Weekly Report · 4d ago
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Seeking Alpha · 04/16 22:25
Janux a new buy at Jones on lead assets for solid tumors
Seeking Alpha · 04/16 18:25
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
Janux Therapeutics has an average 12-month price target of $63.83. The company is a clinical-stage biopharmaceutical company developing next-generation cancer drugs. 6 analysts have provided ratings for JanuxTherapeutics in the latest quarter. The average price target has increased 130.68% from $27.67.
Benzinga · 04/16 12:00
Janux Therapeutics Price Target Announced at $70.00/Share by JonesTrading
Dow Jones · 04/16 11:00
Janux Therapeutics Initiated at Buy by JonesTrading
Dow Jones · 04/16 11:00
JonesTrading Initiates Coverage On Janux Therapeutics with Buy Rating, Announces Price Target of $70
Benzinga · 04/16 10:50
JANUX THERAPEUTICS INC <JANX.O>: JONESTRADING INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $70
Reuters · 04/16 04:44
Buy Rating Affirmed for Janux Therapeutics on Innovative Oncology Treatments and M&A Potential
TipRanks · 04/15 20:15
Validea Detailed Fundamental Analysis - JANX
NASDAQ · 04/15 20:05
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
NASDAQ · 04/15 16:54
Weekly Report: what happened at JANX last week (0408-0412)?
Weekly Report · 04/15 10:04
Noteworthy Thursday Option Activity: JANX, WFC, AMD
NASDAQ · 04/11 19:22
Stock Indexes Rise in Afternoon Trade
NASDAQ · 04/11 17:42
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Fastenal shares dipped 6.7% to $69.73 on Thursday. The company reported worse-than-expected first-quarter financial results. Rallybio Corporation shares climbed 89.6% after company announced a collaboration with Johnson & Johnson. Rent the Runway, Inc. Shares jumped 74.5% after the company reported mixed fourth-quarter results.
Benzinga · 04/11 17:33
Stocks Mixed as Bond Yields Climb
NASDAQ · 04/11 17:07
Technology Stocks Power the Broader Market Higher
Technology stocks led the overall market higher Thursday. Apple closed up more than +4% as chip stocks rallied. The S&P 500 closed up 0.74% and the Nasdaq 100 posted a 1-week high. The ECB held interest rates steady for a fifth consecutive meeting. The 10-year T-note yield rose to a new 4-3/4 month high on hawkish comments from the Fed. Stocks found support after US producer prices rose at a slower-than-expected pace in March.
Barchart · 04/11 15:40
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Enliven Therapeutics shares surged 26% to $24.97 on Thursday. The Dow Jones index fell over 50 points in today's session. Shares of Rallybio Corporation jumped 89.6% after the company announced a collaboration with Johnson & Johnson. U.S. Stocks were mixed on Thursday as Enliven shares rose sharply.
Benzinga · 04/11 14:01
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
NASDAQ · 04/11 13:55
More
Webull provides a variety of real-time JANX stock news. You can receive the latest news about Janux Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.